Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats

European Journal of Pharmacology

Volumn 589, Issue 1-3, 2008, Pages 239-244

  Yamashita, Junji ^a   Nakajima, Kenji ^a   Ohno, Yoichi ^a   Kaneshiro, Yoshiaki ^a   Matsuo, Takato ^a   Tanaka, Hitoshi ^a   Kaneko, Kenji ^a  

^a Research Division   (Japan)

Author keywords

Antithrombin; Nephrotic syndrome; Puromycin aminonucleoside

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; CYTOKINE; PUROMYCIN AMINONUCLEOSIDE; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; EPITHELIUM CELL; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; HYPERLIPIDEMIA; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY TUBULE; MALE; NEPHROSIS; NEPHROTIC SYNDROME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; URINARY CAST;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; APOPTOSIS; BLOOD COAGULATION; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HYPERLIPIDEMIAS; IN SITU NICK-END LABELING; INJECTIONS, INTRAVENOUS; KIDNEY; NEPHROTIC SYNDROME; PROTEINURIA; PUROMYCIN AMINONUCLEOSIDE; RATS; THROMBIN; TIME FACTORS;

EID: 47549100154     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.04.065     Document Type: Article

References (38)

1. Citak A., Emre S., Sâirin A., Bilge I., and Nayir A. Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr. Nephrol. 14 (2000) 138-142
2. Cruz C., Juárez-Nicolás F., Tapie E., Correa-Rotter R., and Pedraza-Chaverrí J. Abnormalities of coagulation in experimental nephrotic syndrome. Nephron 68 (1994) 489-496
3. Eddy A.A., and Michael A.F. Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis. Kidney. Int. 33 (1988) 14-23
4. Eddy A.A., McCulloch L., Liu E., and Adams J. A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am. J. Pathol. 138 (1991) 1111-1123
5. Elwell R.J., Spencer A.P., and Eisele G. Combined furosemide and human albumin treatment for diuretic-resistant edema. Ann. Pharmacother. 37 (2003) 695-700
6. Fernandez L., Romero M., Soto H., and Mosquera J. Increased apoptosis in acute puromycin aminonucleoside nephrosis. Exp. Nephrol. 9 (2001) 99-108
7. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
8. 2- formation. Nephrol. Dial. Transplant. 15 (2000) 339-346
9. Gitlin D., Janeway C.A., and Farr L.E. Studies on the metabolism of plasma proteins in the nephrotic syndrome. I. Albumin, gamma-globulin and iron-binding globulin. J. Clin. Invest. 35 (1956) 44-56
10. Gómez-Chiarri M., Ortiz A., Lerma J.L., López-Armada M.J., Mampaso F., González E., and Egido J. Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats. Lab. Invest. 70 (1994) 449-459
11. Imbasciati E., Gusmano R., Edefonti A., Zucchelli P., Pozzi C., Grassi C., Della Volpe M., Perfumo F., Petrone P., Picca M., Claris Appiani A., Pasquali S., and Ponticelli C. Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome. Br. Med. J. 291 (1985) 1305-1308
12. Kauffmann R.H., Veltkamp J.J., Van Tilburg N.H., and Van Es L.A. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am. J. Med. 65 (1978) 607-613
13. Kaysen G.A., Kirkpatric W.G., and Couser W.G. Albumin homeostasis in the nephrotic rat: nutritional considerations. Am. J. Physiol. 247 (1984) F192-F202
14. Kaysen G.A., Gambertoglio J., Jimenez I., Jones H., and Hutchison F.N. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney. Int. 29 (1986) 572-577
15. Kielar M.L., John R., Bennett M., Richardson J.A., Shelton J.M., Chen L., Jeyarajah D.R., Zhou X.J., Zhou H., Chiquett B., Nagami G.T., and Lu C.Y. Maladaptive role of IL-6 in ischemic acute renal failure. J. Am. Soc. Nephrol. 16 (2005) 3315-3325
16. Kuhn K., Haas-Wohrle A., Lutz-Vorderbrugge A., and Felten H. Treatment of severe nephrotic syndrome. Kidney. Int. Suppl. 64 (1998) S50-S53
17. Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney. Int. 28 (1985) 429-439
18. Mizutani A., Okajima K., Uchiba M., Isobe H., Harada N., Mizutani S., and Noguchi T. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 101 (2003) 3029-3036
19. Okajima K., Ueyama H., Hashimoto Y., Sasaki Y., Matsumoto K., Okabe H., Inoue M., Araki S., and Takatsuki K. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto. Thromb. Haemost. 61 (1989) 20-24
20. Pedreañez A., Rincón J., Romero M., Viera N., and Mosquera J. Melatonin decreases apoptosis and expression of apoptosis-associated proteins in acute puromycin aminonucleoside nephrosis. Nephrol. Dial. Transplant. 19 (2004) 1098-1105
21. Perico N., Benigni A., Zoja C., Delaini F., and Remuzzi G. Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporine A. Am. J. Physiol. 251 (1986) F581-F587
22. Rabelink T.J., Zwaginga J.J., Koomans H.A., and Sixma J.J. Thrombosis and hemostasis in renal disease. Kidney. Int. 46 (1994) 287-296
23. Radhakrishnan J., Appel A.S., Valeri A., and Appel G.B. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am. J. Kidney Dis. 22 (1993) 135-142
24. Rosenberg R.D., and Damus P.S. The purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol. Chem. 248 (1973) 6490-6505
25. Rosenberg R.D. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am. J. Med. 87 (1989) 2S-9S
26. Sarasin F.P., and Schifferli J.A. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney. Int. 45 (1994) 578-585
27. Shiiki H., Sasaki Y., Nishino T., Kimura T., Kurioka H., Fujimoto S., and Dohi K. Cell proliferation and apoptosis of the glomerular epithelial cells in rats with puromycin aminonucleoside nephrosis. Pathobiology 66 (1998) 221-229
28. Sirolli V., Ballone E., Garofalo D., Merciaro G., Settefrati N., Di Mascio R., Di Gregorio P., and Bonomini M. Platelet activation markers in patients with nephrotic syndrome. A comparative study of different platelet function tests. Nephron 91 (2002) 424-430
29. Schwarting A., Wada T., Kinoshita K., Tesch G., and Kelley V.R. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas (lpr) mice. J. Immunol. 161 (1998) 494-503
30. Taylor Jr. F.B., Emerson Jr. T.E., Jordan R., Chang A.K., and Blick K.E. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ. Shock. 26 (1988) 227-235
31. Thomas S.E., Andoh T.F., Pichler R.H., Shankland S.J., Couser W.G., Bennett W.M., and Johnson R.J. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int. 53 (1998) 897-908
32. Truong L.D., Petrusevska G., Yang G., Gurpinar T., Shappell S., Lechago J., Rouse D., and Suki W.N. Cell apoptosis and proliferation in experimental chronic obstructive uropathy. Kidney Int. 50 (1996) 200-207
33. Uchiba M., Okajima K., and Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb. Res. 89 (1998) 233-241
34. van Veen S.Q., Cheung C.W., Meijers J.C., van Gulik T.M., and Boermeester M.A. Anticoagulant and anti-inflammatory effects after peritoneal lavage with antithrombin in experimental polymicrobial peritonitis. J Thromb. Haemost. 4 (2006) 2343-2351
35. Vaziri N.D., Paule P., Toohey J., Hung E., Alilhani S., Darwish R., and Pahl M.V. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch. Intern. Med. 144 (1984) 1802-1803
36. Wang W., Tzanidis A., Divjak M., Thomson N.M., and Stein-Oakley A.N. Altered signaling and regulatory mechanisms of apoptosis in focal and segmental glomerulosclerosis. J. Am. Soc. Nephrol. 12 (2001) 1422-1433
37. Wiedermann C.J. Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit. Care 10 (2006) 209-217
38. Yamauchi T., Umeda F., Inoguchi T., and Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem. Biophys. Res. Commun. 163 (1989) 1404-1411